March 2026 monthly summary for nf-core/modules: Delivered PyCloneVI Output Enhancements and a New Topic Channel, with refinements to the output structure and metadata/versioning artifacts to improve downstream reliability and reproducibility. Added a topic channel to improve result categorization and downstream parsing. Corrected metadata and versioning files to enhance release readiness. Addressed lint issues and minor typos to maintain code quality and CI compatibility.

February 2026: Delivered two major features in caravagnalab/ProCESS-examples enhancing cancer genomics analysis: (1) Subclonal Structure Visualization and Driver Analysis, introducing comprehensive visualizations and analyses for subclonal mutation clustering and driver assessment, with new R scripts for plots that relate mutation processes to subclonal evolution metrics; and (2) Cancer Mutation Signatures Analysis Enhancements, upgrading figure generation/analysis tooling, input parameter handling, and outputs, plus the introduction of univariate analysis for detailed exposure and cross-tool performance comparisons.

January 2026 monthly work summary for caravagnalab/ProCESS-examples. Focused on delivering end-to-end cancer genomics analysis capabilities and sequencing data visualization, with a shift to BASCULE as the signature method, plus enhanced EDF-based data processing pipelines. No major defects reported for this period. Business value realized through unified workflows, faster insights, and scalable visualizations across cancer types. Key technical achievements include consolidated workflows, new R-script-based data processing, improved mutation-signature and tumor mutational burden analytics, and EDF-driven analytics for mutation statistics and sequencing timelines.

Monthly summary for 2025-12 focusing on business value and technical achievements for caravagnalab/ProCESS-examples. Highlights include delivery of enhanced genomic data visualization and CNA analysis, plus a new signature assignment tool for interpreted clusters. No major defects reported in this period.

November 2025 monthly summary for caravagnalab/ProCESS-examples: Delivered significant enhancements to ProCESS Subclonal Analysis and Visualization. Implemented a new file-management option and improved data handling for subclonal analysis. Added visualization scripts for CNA, germline validation metrics, and mutation signatures to improve interpretation of tumor evolution. No major defects reported; minor fixes and refinements were applied across commits. Overall impact includes faster end-to-end analysis, better data interpretation, and stronger alignment with downstream research and clinical decision support.

Month 2025-10 focused on delivering a robust Mutational Signature Analysis Workflow and Visualization Toolchain for caravagnalab/ProCESS-examples, with automation and reliability improvements aimed at enabling researchers to produce accurate mutational signatures and publication-ready visuals. No major defects were reported this month; maintenance prioritized reliability, scalability, and researcher productivity.

September 2025 performance summary: Delivered substantial feature enhancements and workflow improvements across nf-core/modules and ProCESS-examples, focusing on data quality, simulation capabilities, and developer efficiency. Key updates include a refined TINC module for tumor-normal mutation analysis with robust filtering and clearer normal-sample focus, a new SPN07 tumor evolution simulator, repository housekeeping to remove unused assets, and a Battenberg launcher plus resource orchestration to streamline cohort-building and benchmarking. No major bug fixes were required this month; the work emphasized robustness, scalability, and maintainability, delivering tangible business value for downstream analyses and decision-making.

August 2025 delivered a substantive set of enhancements to caravanagl/ProCESS-examples that improve data integrity, visualization accuracy, pipeline scalability, and cross-team collaboration. Focused improvements in memory visualization, CNA analysis integration, validated outputs, and pipeline automation reduce operational friction and support robust, reproducible analyses across SPN simulations and CNA workflows.

July 2025 monthly summary for the ProCESS-examples repository focusing on end-to-end validation enhancements, SPN simulations, signature analysis, somatic validation, and benchmarking configuration. Delivered across CNA validation, cancer signature validation, SPN reporting, somatic validation workflow, and reproducible benchmarking. Overall impact: Improved reliability, reproducibility, and business value through cross-caller validation, richer reporting, and streamlined pipelines, enabling faster, more trustworthy decision support.

June 2025 performance summary: Delivered significant advancements in Sequenza-powered workflows within ProCESS-examples, improved data handling for Tumour Evo and sequencing getters, and tightened reliability across the pipeline. Implemented end-to-end Sequenza integration, added conversion utilities, and introduced parallel processing with write_sh support to boost throughput. Enhanced benchmarking and QC validation, updated sample sheets for Sequenza compatibility, and completed build_cohort sequencing integration with final driver scripts. Documentation and codebase housekeeping were also completed to support maintainability and user adoption.

May 2025 performance highlights for caravagnalab/ProCESS-examples: Focused on delivering robust germline/somatic reporting, strengthening validation and resource checks, improving configuration management, and enhancing deployment workflows. These changes improve data quality, reproducibility, and operational efficiency, enabling faster, more reliable downstream analytics and reporting.

April 2025 performance highlights across caravagnalab/ProCESS-examples and bioconda/bioconda-recipes focused on reproducibility, scalability, and onboarding. Implemented SPN03 final integration (final simulation and removal of legacy SPN03 files) to improve simulation accuracy and code cleanliness. Introduced containerization and batch execution support with a Dockerfile, updated samtools installation, and an sbatch script to enable scalable, reproducible runs. Enhanced sequencing reporting (new map/script/compile reports) and fixed report generation. Undertook comprehensive documentation overhaul with README updates and scaffolding/rename work to streamline onboarding. Expanded Bioconda coverage by adding packaging recipes for two new R packages (r-easypar and r-bmix) to simplify build, dependencies, and distribution.

March 2025 performance summary for caravagnalab/ProCESS-examples: Key features delivered include a Germline variant validation and cross-chromosome comparison pipeline across chromosomes 1-22, with multi-caller VCF parsing, reference-merging against rRACES, and generation of performance metrics and visualizations under configurable filters. Another feature delivered: Enhanced reporting visuals in the R Markdown report, featuring a new phylogenetic forest plot, improved visualization of driver events and copy number alterations, and refined signature exposure plots with improved layout and color mapping. Major bugs fixed: none identified this month; minor refinements were applied to germline validation and plotting components. Overall impact: strengthens end-to-end QC and benchmarking for germline variant analysis, enabling more robust cross-caller performance assessment and clearer, publication-ready reporting. Technologies/skills demonstrated: Python/R pipelines for VCF parsing and cross-caller comparisons, data integration with reference datasets (rRACES), performance metric computation, and advanced data visualization in R Markdown including phylogenetic forest plots and color-mapped plots.

February 2025: ProCESS-examples delivered targeted improvements to usability, reproducibility, and scalability. Major repo restructuring, enhanced data interpretation with ASCAT/CNA parsing, HPC-ready batch execution, and benchmark visualization capabilities were introduced, driving faster onboarding, more reliable analyses, and scalable deployment.

Concise monthly summary for 2024-11 focusing on key features delivered and technical/business impact for performance reviews.